Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Lifitegrast

Eye drops for dry eye disease, approved in the United States in 2016: it mimics the docking site of the ICAM-1 protein and blocks the LFA-1 receptor on T lymphocytes, calming inflammation on the eye's surface. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?Many patients notice an unusual taste in the mouth after the drops: the solution probably drains through the tear ducts, which connect the eye to the nose and throat.

LifitegrastGo to the active ingredient →
LifitegrastActive ingredientLifitegrastCat. No. P-L063-001CAS 1025967-78-5
O-HBTUImpurityO-HBTUCat. No. P-L063-067CAS 625384-22-7

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.